Test Price
2,800 AED✅ Home Collection Available
NCF1 Gene Chronic Granulomatous Disease (Cytochrome b-Positive, Type 1) Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
This targeted next-generation sequencing (NGS) test confirms autosomal recessive chronic granulomatous disease type 1 by analyzing the NCF1 gene with 99.9% diagnostic sensitivity. Designed for UAE families, it delivers definitive molecular results from a simple blood draw, supported by post-test clinical guidance and direct insurance verification.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced targeted NGS test interrogates the full coding region of the NCF1 gene to detect pathogenic variants responsible for autosomal recessive chronic granulomatous disease (CGD) type 1, a primary immunodeficiency characterised by cytochrome b positivity. The assay provides UAE families with a definitive genetic diagnosis, guiding tailored prophylactic and therapeutic strategies including antimicrobial prophylaxis, immunomodulation, and haematopoietic stem cell transplantation planning.
| Feature | Our NCF1 NGS Test | Whole Exome Sequencing (Alternative) |
|---|---|---|
| Precision | Greater than 99% sensitivity and specificity for NCF1 mutations | Broad coverage but lower depth for individual genes |
| Methodology | Targeted NGS with full coding region analysis | Whole exome capture and sequencing |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks (often with incidental findings analysis) |
Physician Insight & Safety Protocols
“As a DHA-licensed consultant in medical genetics, I recognise the complexity that accompanies a diagnosis of chronic granulomatous disease. A pathogenic variant in NCF1 confirms the molecular subtype and directs targeted management, yet a negative result does not exclude other causes of phagocyte dysfunction. I strongly advise all patients to review their results with our genetics team before initiating or altering any treatment plan.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory – Medication Continuation
Do not discontinue prescribed prophylactic antibiotics, antifungal agents, or immunomodulatory therapy without consulting your physician. Interruption of prophylaxis may precipitate severe bacterial or fungal infections in patients with suspected or confirmed CGD.
Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not a substitute for acute clinical management. Active severe infections require immediate hospital evaluation and empiric therapy.
- Red Flags: If the patient develops new high fever, respiratory distress, or signs of sepsis, seek emergency medical attention regardless of pending genetic results.
- Clinical Correlation: Results must be interpreted alongside functional neutrophil oxidative burst assays (e.g., dihydrorhodamine flow cytometry) for complete immune assessment.
Patient FAQ & Clinical Guidance
1. What is the NCF1 gene test for?
This targeted NGS test detects disease-causing mutations in the NCF1 gene, which causes autosomal recessive chronic granulomatous disease type 1. It provides a definitive molecular diagnosis for patients with recurrent bacterial or fungal infections and suspected CGD, enabling early intervention, tailored prophylaxis, and family cascade screening.
2. Why is genetic counseling required before testing?
Pre-test genetic counseling helps interpret the family inheritance pattern, ensures that the correct test is ordered, and prepares you for possible outcomes. The session reviews the autosomal recessive pedigree, explains recurrence risks for future pregnancies, and addresses implications for at-risk relatives who may benefit from early screening.
3. How is the sample collected?
A peripheral whole blood sample is collected at your home by a DHA-licensed phlebotomist using strict cold-chain protocol. The procedure is quick and can be scheduled at your convenience between 8 AM and 11 PM daily. Alternatively, an FTA card dried blood spot may be used for remote submission.
UAE Regulatory & Data Privacy Adherence
Compliance: This service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed under strict confidentiality protocols with ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139). Patient consent and clinical safety follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | NCF1 Gene Chronic Granulomatous Disease (Cytochrome b-Positive, Type 1) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood or FTA card dried blood spot |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with full coding region analysis |
| ICD-10-CM Code | D82.0 |
| LOINC Code | 21649-1 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians